{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:39:14Z","timestamp":1770640754508,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10928-024-09947-2","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T14:58:01Z","timestamp":1733410681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Semi-mechanistic population pharmacokinetic modeling of DZIF-10c, a neutralizing antibody against SARS-Cov-2: predicting systemic and lung exposure following inhaled and intravenous administration"],"prefix":"10.1007","volume":"52","author":[{"given":"Sree","family":"Kurup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves Velez","family":"de Mendizabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Bolella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy","family":"De Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Gruell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob J","family":"Malin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Korell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"issue":"8","key":"9947_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa2001017","journal-title":"N Engl J Med"},{"issue":"10223","key":"9947_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507\u2013513. https:\/\/doi.org\/10.1016\/S0140-6736(20)30211-7","journal-title":"Lancet"},{"issue":"3","key":"9947_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis HE, McCorkell L, Vogel JM, Topol EJ (2023) Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21(3):133\u2013146. https:\/\/doi.org\/10.1038\/s41579-022-00846-2","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"9947_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 383(2):120\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa2015432","journal-title":"N Engl J Med"},{"issue":"7","key":"9947_CR5","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/jth.14869","volume":"18","author":"JF Llitjos","year":"2020","unstructured":"Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, Merouani K (2020) High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 18(7):1743\u20131746. https:\/\/doi.org\/10.1111\/jth.14869","journal-title":"J Thromb Haemost"},{"issue":"1","key":"9947_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/epidemiologia3010006","volume":"3","author":"S Dom\u00e8nech-Montoliu","year":"2022","unstructured":"Dom\u00e8nech-Montoliu S, Puig-Barber\u00e0 J, Pac-Sa MR, Vidal-Utrillas P, Latorre-Poveda M, Del Rio-Gonz\u00e1lez A et al (2022) Complications post-COVID-19 and risk factors among patients after six months of a SARS-CoV-2 infection: a population-based prospective cohort study. Epidemiologia (Basel) 3(1):49\u201367. https:\/\/doi.org\/10.3390\/epidemiologia3010006","journal-title":"Epidemiologia (Basel)"},{"issue":"11","key":"9947_CR7","doi-asserted-by":"publisher","first-page":"e1004122","DOI":"10.1371\/journal.pmed.1004122","volume":"19","author":"M Roessler","year":"2022","unstructured":"Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O et al (2022) Post-COVID-19-associated morbidity in children, adolescents, and adults: a matched cohort study including more than 157,000 individuals with COVID-19 in Germany. PLoS Med 19(11):e1004122. https:\/\/doi.org\/10.1371\/journal.pmed.1004122","journal-title":"PLoS Med"},{"issue":"11","key":"9947_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra2206573","volume":"387","author":"DH Barouch","year":"2022","unstructured":"Barouch DH (2022) Covid-19 vaccines - immunity, variants, boosters. N Engl J Med 387(11):1011\u20131020. https:\/\/doi.org\/10.1056\/NEJMra2206573","journal-title":"N Engl J Med"},{"issue":"6","key":"9947_CR9","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.immuni.2022.05.005","volume":"55","author":"H Gruell","year":"2022","unstructured":"Gruell H, Vanshylla K, Weber T, Barnes CO, Kreer C, Klein F (2022) Antibody-mediated neutralization of SARS-CoV-2. Immunity 55(6):925\u2013944. https:\/\/doi.org\/10.1016\/j.immuni.2022.05.005","journal-title":"Immunity"},{"key":"9947_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-med-042420-113838","volume":"73","author":"D Li","year":"2022","unstructured":"Li D, Sempowski GD, Saunders KO, Acharya P, Haynes BF (2022) SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment. Annu Rev Med 73:1\u201316. https:\/\/doi.org\/10.1146\/annurev-med-042420-113838","journal-title":"Annu Rev Med"},{"key":"9947_CR11","doi-asserted-by":"publisher","unstructured":"de Almeida Oliveira A, Praia Borges Freire D, Rodrigues de Andrade A, de Miranda Marques A, da Silva Madeira L, Moreno Senna JP, Freitas Brasileiro da Silveira IA, de Castro Fialho B (2023) The landscape of neutralizing monoclonal antibodies (nAbs) for treatment and prevention of COVID-19. J Pharm Innov:1\u201319. https:\/\/doi.org\/10.1007\/s12247-023-09713-w","DOI":"10.1007\/s12247-023-09713-w"},{"key":"9947_CR12","doi-asserted-by":"publisher","unstructured":"Halwe S, Kupke A, Vanshylla K, Liberta F, Gruell H, Zehner M et al (2021) Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection. Viruses 13(8). https:\/\/doi.org\/10.3390\/v13081498","DOI":"10.3390\/v13081498"},{"issue":"1","key":"9947_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","volume":"23","author":"CB Jackson","year":"2022","unstructured":"Jackson CB, Farzan M, Chen B, Choe H (2022) Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 23(1):3\u201320. https:\/\/doi.org\/10.1038\/s41580-021-00418-x","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"24","key":"9947_CR14","doi-asserted-by":"publisher","first-page":"12161","DOI":"10.1128\/jvi.75.24.12161-12168.2001","volume":"75","author":"M Hezareh","year":"2001","unstructured":"Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW (2001) Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 75(24):12161\u201312168. https:\/\/doi.org\/10.1128\/jvi.75.24.12161-12168.2001","journal-title":"J Virol"},{"key":"9947_CR15","doi-asserted-by":"publisher","unstructured":"Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S (2011) Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 3. 161\u201366. https:\/\/doi.org\/10.4161\/mabs.3.1.13799","DOI":"10.4161\/mabs.3.1.13799"},{"key":"9947_CR16","unstructured":"Cynbiose (2021) Assessment of the antiviral efficacy of two prophylactic nebulizations of the antibody BI 767551 (dose: 10 mL) in 4 cynomolgus monkeys as compared to that of the vehicle in two control animals, prior to their infection with SARS-CoV-2. Study 046\/15."},{"key":"9947_CR17","unstructured":"ClinicalTrials.gov (2020) SARS-CoV-2-neutralizing monoclonal COVID-19 antibody DZIF-10c by infusion. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000. https:\/\/clinicaltrials.gov\/study\/NCT04631666 NLM Identifier: NCT04631666 (Last accessed July 2, 2024)"},{"key":"9947_CR18","unstructured":"ClinicalTrials.gov (2020) SARS-CoV-2-neutralizing monoclonal COVID-19 antibody DZIF-10c by inhalation. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000. https:\/\/clinicaltrials.gov\/study\/NCT04631705 NLM Identifier: NCT04631705 (Last accessed July 2, 2024)"},{"issue":"22","key":"9947_CR19","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1111\/bph.15621","volume":"178","author":"MW Sadiq","year":"2021","unstructured":"Sadiq MW, Holz O, Ellinghusen BD, Faulenbach C, M\u00fcller M, Badorrek P, Eriksson UG, Frid\u00e9n M, Stomilovic S, Lundqvist AJ, Hohlfeld JM (2021) Lung pharmacokinetics of inhaled and systemic drugs: a clinical evaluation. Br J Pharmacol 178(22):4440\u20134451. https:\/\/doi.org\/10.1111\/bph.15621","journal-title":"Br J Pharmacol"},{"issue":"2","key":"9947_CR20","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1152\/jappl.1986.60.2.532","volume":"60","author":"SI Rennard","year":"1986","unstructured":"Rennard SI, Basset G, Lecossier D, O\u2019Donnell KM, Pinkston P, Martin PG, Crystal RG (1986) Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol (1985) 60(2):532\u2013538. https:\/\/doi.org\/10.1152\/jappl.1986.60.2.532","journal-title":"J Appl Physiol (1985)"},{"issue":"10","key":"9947_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49(10):633\u2013659. https:\/\/doi.org\/10.2165\/11535960-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"9947_CR22","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/psp4.12422","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ (2019) NONMEM tutorial part II: estimation methods and advanced examples. CPT Pharmacometrics Syst Pharmacol 8(8):538\u2013556. https:\/\/doi.org\/10.1002\/psp4.12422","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"9947_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151. https:\/\/doi.org\/10.1208\/s12248-011-9255-z","journal-title":"AAPS J"},{"issue":"2","key":"9947_CR24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentre F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90(2):154\u2013166. https:\/\/doi.org\/10.1016\/j.cmpb.2007.12.002","journal-title":"Comput Methods Programs Biomed"},{"key":"9947_CR25","first-page":"1","volume":"2022","author":"US Food and Drug Administration Center for Drug Evaluation and Research (CDER)","year":"2022","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2022) Population pharmacokinetics. Guidance for industry. February 2022:1\u201327. https:\/\/www.fda.gov\/media\/128793\/download","journal-title":"February"},{"key":"9947_CR26","volume-title":"Bayesian data analysis","author":"A Gelman","year":"2004","unstructured":"Gelman A, Carlin JB, Stern HS, Rubin DB (2004) Bayesian data analysis. Chapman & Hall\/CRC, New York"},{"issue":"2","key":"9947_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/a:1011555016423","volume":"28","author":"Y Yano","year":"2001","unstructured":"Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28(2):171\u2013192. https:\/\/doi.org\/10.1023\/a:1011555016423","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9947_CR28","unstructured":"Vira Therapeutics GmbH (2021) Neutralization of authentic SARS-CoV-2 variants with DZIF-10c, March 18, 2021. Report No.: VoC VNT 001"},{"issue":"2","key":"9947_CR29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/psp4.13088","volume":"13","author":"CK Johnston","year":"2024","unstructured":"Johnston CK, Waterhouse T, Wiens M, Mondick J, French J, Gillespie WR (2024) Bayesian estimation in NONMEM. CPT Pharmacometrics Syst Pharmacol 13(2):192\u2013207. https:\/\/doi.org\/10.1002\/psp4.13088","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9947_CR30","unstructured":"Applied Research Associates Multiple-path particle dosimetry (mppd v 3.04) model, https:\/\/www.ara.com\/mppd\/"},{"issue":"2","key":"9947_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/bdd.1952","volume":"37","author":"J Wang","year":"2016","unstructured":"Wang J, Iyer S, Fielder PJ, Davis JD, Deng R (2016) Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. Biopharm Drug Dispos 37(2):51\u201365. https:\/\/doi.org\/10.1002\/bdd.1952","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"9947_CR32","doi-asserted-by":"publisher","first-page":"1964935","DOI":"10.1080\/19420862.2021.1964935","volume":"13","author":"E Germovsek","year":"2021","unstructured":"Germovsek E, Cheng M, Giragossian C (2021) Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings. MAbs 13(1):1964935. https:\/\/doi.org\/10.1080\/19420862.2021.1964935","journal-title":"MAbs"},{"issue":"1","key":"9947_CR33","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1038\/s41467-020-19057-5","volume":"11","author":"J Fajnzylber","year":"2020","unstructured":"Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A et al (2020) SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun 11(1):5493. https:\/\/doi.org\/10.1038\/s41467-020-19057-5","journal-title":"Nat Commun"},{"issue":"2","key":"9947_CR34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1164\/rccm.202009-3386LE","volume":"203","author":"K Roedl","year":"2021","unstructured":"Roedl K, Heidenreich S, Pfefferle S, Jarczak D, Urbanowicz TT, Norz D, Aepfelbacher M, Kroger N, Kluge S, Lutgehetmann M, Christopeit M, Wichmann D (2021) Viral dynamics of SARS-CoV-2 in critically ill allogeneic hematopoietic stem cell transplant recipients and immunocompetent patients with COVID-19. Am J Respir Crit Care Med 203(2):242\u2013245. https:\/\/doi.org\/10.1164\/rccm.202009-3386LE","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"9947_CR35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s13054-020-03398-0","volume":"24","author":"JF Bermejo-Martin","year":"2020","unstructured":"Bermejo-Martin JF, Gonzalez-Rivera M, Almansa R, Micheloud D, Tedim AP, Dominguez-Gil M et al (2020) Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. Crit Care 24(1):691. https:\/\/doi.org\/10.1186\/s13054-020-03398-0","journal-title":"Crit Care"},{"issue":"7809","key":"9947_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","volume":"581","author":"R W\u00f6lfel","year":"2020","unstructured":"W\u00f6lfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, M\u00fcller MA et al (2020) Virological assessment of hospitalized patients with COVID-2019. Nature 581(7809):465\u2013469. https:\/\/doi.org\/10.1038\/s41586-020-2196-x","journal-title":"Nature"},{"issue":"3","key":"9947_CR37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jinf.2020.06.067","volume":"81","author":"KA Walsh","year":"2020","unstructured":"Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, Ahern S, Carty PG, O\u2019Brien KK, O\u2019Murchu E, O\u2019Neill M, Smith SM, Ryan M, Harrington P (2020) SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect 81(3):357\u2013371. https:\/\/doi.org\/10.1016\/j.jinf.2020.06.067","journal-title":"J Infect"},{"issue":"3","key":"9947_CR38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/cpt.2459","volume":"111","author":"E Chigutsa","year":"2022","unstructured":"Chigutsa E, Jordie E, Riggs M, Nirula A, Elmokadem A, Knab T, Chien JY (2022) A quantitative modeling and simulation framework to support candidate and dose selection of anti-SARS-CoV-2 monoclonal antibodies to advance bamlanivimab into a first-in-human clinical trial. Clin Pharmacol Ther 111(3):595\u2013604. https:\/\/doi.org\/10.1002\/cpt.2459","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"9947_CR39","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.xphs.2023.01.001","volume":"112","author":"E Boger","year":"2023","unstructured":"Boger E, Erngren T, Fihn BM, Leonard E, Rubin K, B\u00e4ckstr\u00f6m E (2023) Assessment of epithelial lining fluid partitioning of systemically administered monoclonal antibodies in rats. J Pharm Sci 112(4):1130\u20131136. https:\/\/doi.org\/10.1016\/j.xphs.2023.01.001","journal-title":"J Pharm Sci"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09947-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-024-09947-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09947-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T22:05:31Z","timestamp":1739657131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-024-09947-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["9947"],"URL":"https:\/\/doi.org\/10.1007\/s10928-024-09947-2","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SK, EB,\u00a0DDS, US and JK were all full-time employees of Boehringer Ingelheim when the study analysis was conducted. NVDM was an employee of Metrum Research Group at the time of this analysis. HG, FK, and SB are inventors on patent applications on neutralizing antibodies and have received payments from the University of Cologne and the Philipps University of Marburg for licensed antibodies. NVM is an employee of Gilead and former employee of Metrum Research Group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients enrolled in the clinical trials provided written informed consent to participate. No identifying information for individual patients is included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"3"}}